 | • レポートコード：20QY06-08491 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、慢性炎症性脱髄性多発神経障害薬のグローバル市場について種類別（GNbAC-1、GL-2045、ビオチン、その他）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・慢性炎症性脱髄性多発神経障害薬市場の概要 ・世界の主要地域別慢性炎症性脱髄性多発神経障害薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の慢性炎症性脱髄性多発神経障害薬市場規模2015-2026：種類別（GNbAC-1、GL-2045、ビオチン、その他） ・世界の慢性炎症性脱髄性多発神経障害薬市場規模2015-2026：用途別（病院、クリニック、その他） ・慢性炎症性脱髄性多発神経障害薬の北米市場規模2015-2020 ・慢性炎症性脱髄性多発神経障害薬のヨーロッパ市場規模2015-2020 ・慢性炎症性脱髄性多発神経障害薬の中国市場規模2015-2020 ・慢性炎症性脱髄性多発神経障害薬の日本市場規模2015-2020 ・慢性炎症性脱髄性多発神経障害薬の東南アジア市場規模2015-2020 ・慢性炎症性脱髄性多発神経障害薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （CSL Ltd、GeNeuro SA、MedDay SA、Octapharma AG、Pfizer Inc、Takeda、Teijin Pharma Ltd） ・慢性炎症性脱髄性多発神経障害薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・慢性炎症性脱髄性多発神経障害薬の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market
The global Chronic Inflammatory Demyelinating Polyneuropathy Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Scope and Market Size
The global Chronic Inflammatory Demyelinating Polyneuropathy Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Inflammatory Demyelinating Polyneuropathy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Chronic Inflammatory Demyelinating Polyneuropathy Drug market is segmented into
GNbAC-1
GL-2045
Biotin
Others
Segment by Application, the Chronic Inflammatory Demyelinating Polyneuropathy Drug market is segmented into
Hospital
Clinic
Others
The Chronic Inflammatory Demyelinating Polyneuropathy Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Chronic Inflammatory Demyelinating Polyneuropathy Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Share Analysis
Chronic Inflammatory Demyelinating Polyneuropathy Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chronic Inflammatory Demyelinating Polyneuropathy Drug business, the date to enter into the Chronic Inflammatory Demyelinating Polyneuropathy Drug market, Chronic Inflammatory Demyelinating Polyneuropathy Drug product introduction, recent developments, etc.
The major vendors covered:
CSL Ltd
GeNeuro SA
MedDay SA
Octapharma AG
Pfizer Inc
Takeda
Teijin Pharma Ltd
…
Table of Contents
1 Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Overview
1.1 Chronic Inflammatory Demyelinating Polyneuropathy Drug Product Scope
1.2 Chronic Inflammatory Demyelinating Polyneuropathy Drug Segment by Type
1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales by Type (2020-2026)
1.2.2 GNbAC-1
1.2.3 GL-2045
1.2.4 Biotin
1.2.5 Others
1.3 Chronic Inflammatory Demyelinating Polyneuropathy Drug Segment by Application
1.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Growth Rate (2015-2026)
1.4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price Trends (2015-2026)
2 Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimate and Forecast by Region
2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Market Share by Region (2015-2020)
2.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
2.4.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
2.4.3 China Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
2.4.4 Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
2.4.6 India Chronic Inflammatory Demyelinating Polyneuropathy Drug Estimates and Projections (2015-2026)
3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Competition Landscape by Players
3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy Drug Players by Sales (2015-2020)
3.2 Global Top Chronic Inflammatory Demyelinating Polyneuropathy Drug Players by Revenue (2015-2020)
3.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy Drug as of 2019)
3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Average Price by Company (2015-2020)
3.5 Manufacturers Chronic Inflammatory Demyelinating Polyneuropathy Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Chronic Inflammatory Demyelinating Polyneuropathy Drug Players (Opinion Leaders)
4 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Size by Type
4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price by Type (2014-2020)
4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price Forecast by Type (2021-2026)
5 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Size by Application
5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price by Application (2015-2020)
5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price Forecast by Application (2021-2026)
3 North America Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
3.2 North America Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
3.3 North America Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
3.4 North America Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
4 Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
4.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
4.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
4.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
5 China Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
5.2 China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
5.3 China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
5.4 China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
6 Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
6.2 Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
6.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
6.4 Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
7 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
7.2 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
8 India Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Facts & Figures
8.2 India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
8.3 India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
8.4 India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Chronic Inflammatory Demyelinating Polyneuropathy Drug Business
12.1 CSL Ltd
12.1.1 CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.1.2 CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.1.3 CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.1.5 CSL Ltd Recent Development
12.2 GeNeuro SA
12.2.1 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.2.2 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.2.3 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.2.5 GeNeuro SA Recent Development
12.3 MedDay SA
12.3.1 MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.3.2 MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.3.3 MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.3.5 MedDay SA Recent Development
12.4 Octapharma AG
12.4.1 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.4.2 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.4.3 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.4.5 Octapharma AG Recent Development
12.5 Pfizer Inc
12.5.1 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.5.2 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.5.3 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.5.5 Pfizer Inc Recent Development
12.6 Takeda
12.6.1 Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.6.2 Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.6.3 Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.6.5 Takeda Recent Development
12.7 Teijin Pharma Ltd
12.7.1 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Corporation Information
12.7.2 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Business Overview and Total Revenue
12.7.3 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Products Offered
12.7.5 Teijin Pharma Ltd Recent Development
…
13 Chronic Inflammatory Demyelinating Polyneuropathy Drug Manufacturing Cost Analysis
13.1 Chronic Inflammatory Demyelinating Polyneuropathy Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Chronic Inflammatory Demyelinating Polyneuropathy Drug
13.4 Chronic Inflammatory Demyelinating Polyneuropathy Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Chronic Inflammatory Demyelinating Polyneuropathy Drug Distributors List
14.3 Chronic Inflammatory Demyelinating Polyneuropathy Drug Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Region (2015-2020)
Table 6. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Region (2015-2020)
Table 8. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Share by Company (2015-2020)
Table 14. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Company (2015-2020)
Table 16. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy Drug as of 2019)
Table 17. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Chronic Inflammatory Demyelinating Polyneuropathy Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Chronic Inflammatory Demyelinating Polyneuropathy Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Chronic Inflammatory Demyelinating Polyneuropathy Drug Players
Table 22. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Share by Type (2015-2020)
Table 24. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Share by Type (2021-2026)
Table 27. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Type (2021-2026)
Table 29. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Share by Application (2015-2020)
Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Share by Application (2021-2026)
Table 36. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Application (2021-2026)
Table 38. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 41. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 43. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 51. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 53. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 55. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
Table 69. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company (2015-2020)
Table 71. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type (2015-2020)
Table 73. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application (2015-2020)
Table 75. CSL Ltd Corporation Information
Table 76. CSL Ltd Description and Business Overview
Table 77. CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. CSL Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 79. CSL Ltd Recent Development
Table 80. GeNeuro SA Corporation Information
Table 81. GeNeuro SA Description and Business Overview
Table 82. GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 84. GeNeuro SA Recent Development
Table 85. MedDay SA Corporation Information
Table 86. MedDay SA Description and Business Overview
Table 87. MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. MedDay SA Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 89. MedDay SA Recent Development
Table 90. Octapharma AG Corporation Information
Table 91. Octapharma AG Description and Business Overview
Table 92. Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 94. Octapharma AG Recent Development
Table 95. Pfizer Inc Corporation Information
Table 96. Pfizer Inc Description and Business Overview
Table 97. Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 99. Pfizer Inc Recent Development
Table 100. Takeda Corporation Information
Table 101. Takeda Description and Business Overview
Table 102. Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Takeda Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 104. Takeda Recent Development
Table 105. Teijin Pharma Ltd Corporation Information
Table 106. Teijin Pharma Ltd Description and Business Overview
Table 107. Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy Drug Product
Table 109. Teijin Pharma Ltd Recent Development
Table 110. Production Base and Market Concentration Rate of Raw Material
Table 111. Key Suppliers of Raw Materials
Table 112. Chronic Inflammatory Demyelinating Polyneuropathy Drug Distributors List
Table 113. Chronic Inflammatory Demyelinating Polyneuropathy Drug Customers List
Table 114. Market Key Trends
Table 115. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 116. Key Challenges
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy Drug Product Picture
Figure 2. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Others Examples
Figure 9. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Chronic Inflammatory Demyelinating Polyneuropathy Drug Players Market Share by Revenue in Chronic Inflammatory Demyelinating Polyneuropathy Drug 2015 & 2019
Figure 27. Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Type (2015-2020)
Figure 29. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Share by Application (2015-2020)
Figure 31. Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 33. United States Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 34. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company in 2019
Figure 35. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 36. Europe Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application in 2019
Figure 37. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company in 2019
Figure 38. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 39. China Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application in 2019
Figure 40. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company in 2019
Figure 41. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 42. Japan Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application in 2019
Figure 46. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Company in 2019
Figure 47. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Type in 2019
Figure 48. India Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Share by Application in 2019
Figure 49. CSL Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. GeNeuro SA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. MedDay SA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Octapharma AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Pfizer Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Teijin Pharma Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Key Raw Materials Price Trend
Figure 57. Manufacturing Cost Structure of Chronic Inflammatory Demyelinating Polyneuropathy Drug
Figure 58. Manufacturing Process Analysis of Chronic Inflammatory Demyelinating Polyneuropathy Drug
Figure 59. Chronic Inflammatory Demyelinating Polyneuropathy Drug Industrial Chain Analysis
Figure 60. Channels of Distribution
Figure 61. Distributors Profiles
Figure 62. Porter's Five Forces Analysis
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
慢性蕁麻疹または蕁麻疹薬の世界市場レポート2020 Market Analysis and Insights: Global Chronic Urticaria Or Hives Drug Market The global Chronic Urticaria Or Hives Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Chronic Urticaria Or Hives Drug Scope…- 家族性アミロイド多発神経障害の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Familial Amyloid Polyneuropathy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Familial Amyl…
- 慢性膵炎苦痛の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Chronic Pancreatitis Pain market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Chronic Pancreatiti…
- 柔毛膜性生殖腺刺激ホルモンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Chronic Gonadotropin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Chronic Gonadotropin mar…
- 慢性腰痛治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Chronic Low Back Pain Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Chronic Low B…